The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth

Janet K. Parrish, Tyler S. McCann, Marybeth Sechler, Lays M. Sobral, Wenhua Ren, Kenneth L. Jones, Aik-Choon Tan, Paul Jedlicka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Ewing Sarcoma is an aggressive malignant neoplasm affecting children and young adults. Ewing Sarcoma is driven by transcription factor fusion oncoproteins, most commonly EWS/Fli1. While some patients can be cured with high-dose, multiagent, chemotherapy, those that cannot currently have few options. Targeting of the driver oncofusion remains a logical therapeutic approach, but has proven difficult. Recent work has pointed to epigenetic mechanisms as key players, and potential new therapeutic targets, in Ewing Sarcoma. In this study we examined the activity of the pan-JHDM pharmacologic inhibitor JIB-04 in this disease. We show that JIB-04 potently inhibits the growth and viability of Ewing Sarcoma cells, and also impairs tumor xenograft growth. Effects on histone methylation at growth-inhibitory doses vary among cell lines, with most cell lines exhibiting increased total H3K27me3 levels, and some increased H3K4me3 and H3K9me3. JIB-04 treatment widely alters expression of oncogenic and tumor suppressive pathways, including downregulation of known oncogenic members of the Homeobox B and D clusters. JIB-04 also disrupts the EWS/Fli1 expression signature, including downregulation of pro-proliferative pathways normally under positive oncofusion control. Interestingly, these changes are accompanied by increased levels of the EWS/Fli1 oncofusion, suggesting that the drug could be uncoupling EWS/Fli1 from its oncogenic program. All Ewing Sarcoma cell lines examined also manifest increased DNA damage upon JIB-04 treatment. Together, the findings suggest that JIB-04 acts via multiple mechanisms to compromise Ewing Sarcoma cell growth and viability.

Original languageEnglish
Pages (from-to)33110-33123
Number of pages14
JournalOncotarget
Volume9
Issue number69
DOIs
Publication statusPublished - 2018 Sep 1
Externally publishedYes

Fingerprint

Histone Demethylases
Ewing's Sarcoma
DNA Damage
Cell Survival
Cell Proliferation
Growth
Neoplasms
Cell Line
Down-Regulation
Homeobox Genes
Oncogene Proteins
Therapeutics
Heterografts
Epigenomics
Histones
Methylation
JIB-04
Young Adult
Transcription Factors
Drug Therapy

Keywords

  • Demethylase
  • Epigenetics
  • Ewing Sarcoma
  • Inhibitor
  • Jumonji

ASJC Scopus subject areas

  • Oncology

Cite this

The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. / Parrish, Janet K.; McCann, Tyler S.; Sechler, Marybeth; Sobral, Lays M.; Ren, Wenhua; Jones, Kenneth L.; Tan, Aik-Choon; Jedlicka, Paul.

In: Oncotarget, Vol. 9, No. 69, 01.09.2018, p. 33110-33123.

Research output: Contribution to journalArticle

Parrish, Janet K. ; McCann, Tyler S. ; Sechler, Marybeth ; Sobral, Lays M. ; Ren, Wenhua ; Jones, Kenneth L. ; Tan, Aik-Choon ; Jedlicka, Paul. / The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. In: Oncotarget. 2018 ; Vol. 9, No. 69. pp. 33110-33123.
@article{afa43b6c37c1439c86dbe8d0584fe94a,
title = "The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth",
abstract = "Ewing Sarcoma is an aggressive malignant neoplasm affecting children and young adults. Ewing Sarcoma is driven by transcription factor fusion oncoproteins, most commonly EWS/Fli1. While some patients can be cured with high-dose, multiagent, chemotherapy, those that cannot currently have few options. Targeting of the driver oncofusion remains a logical therapeutic approach, but has proven difficult. Recent work has pointed to epigenetic mechanisms as key players, and potential new therapeutic targets, in Ewing Sarcoma. In this study we examined the activity of the pan-JHDM pharmacologic inhibitor JIB-04 in this disease. We show that JIB-04 potently inhibits the growth and viability of Ewing Sarcoma cells, and also impairs tumor xenograft growth. Effects on histone methylation at growth-inhibitory doses vary among cell lines, with most cell lines exhibiting increased total H3K27me3 levels, and some increased H3K4me3 and H3K9me3. JIB-04 treatment widely alters expression of oncogenic and tumor suppressive pathways, including downregulation of known oncogenic members of the Homeobox B and D clusters. JIB-04 also disrupts the EWS/Fli1 expression signature, including downregulation of pro-proliferative pathways normally under positive oncofusion control. Interestingly, these changes are accompanied by increased levels of the EWS/Fli1 oncofusion, suggesting that the drug could be uncoupling EWS/Fli1 from its oncogenic program. All Ewing Sarcoma cell lines examined also manifest increased DNA damage upon JIB-04 treatment. Together, the findings suggest that JIB-04 acts via multiple mechanisms to compromise Ewing Sarcoma cell growth and viability.",
keywords = "Demethylase, Epigenetics, Ewing Sarcoma, Inhibitor, Jumonji",
author = "Parrish, {Janet K.} and McCann, {Tyler S.} and Marybeth Sechler and Sobral, {Lays M.} and Wenhua Ren and Jones, {Kenneth L.} and Aik-Choon Tan and Paul Jedlicka",
year = "2018",
month = "9",
day = "1",
doi = "10.18632/oncotarget.26011",
language = "English",
volume = "9",
pages = "33110--33123",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "69",

}

TY - JOUR

T1 - The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth

AU - Parrish, Janet K.

AU - McCann, Tyler S.

AU - Sechler, Marybeth

AU - Sobral, Lays M.

AU - Ren, Wenhua

AU - Jones, Kenneth L.

AU - Tan, Aik-Choon

AU - Jedlicka, Paul

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Ewing Sarcoma is an aggressive malignant neoplasm affecting children and young adults. Ewing Sarcoma is driven by transcription factor fusion oncoproteins, most commonly EWS/Fli1. While some patients can be cured with high-dose, multiagent, chemotherapy, those that cannot currently have few options. Targeting of the driver oncofusion remains a logical therapeutic approach, but has proven difficult. Recent work has pointed to epigenetic mechanisms as key players, and potential new therapeutic targets, in Ewing Sarcoma. In this study we examined the activity of the pan-JHDM pharmacologic inhibitor JIB-04 in this disease. We show that JIB-04 potently inhibits the growth and viability of Ewing Sarcoma cells, and also impairs tumor xenograft growth. Effects on histone methylation at growth-inhibitory doses vary among cell lines, with most cell lines exhibiting increased total H3K27me3 levels, and some increased H3K4me3 and H3K9me3. JIB-04 treatment widely alters expression of oncogenic and tumor suppressive pathways, including downregulation of known oncogenic members of the Homeobox B and D clusters. JIB-04 also disrupts the EWS/Fli1 expression signature, including downregulation of pro-proliferative pathways normally under positive oncofusion control. Interestingly, these changes are accompanied by increased levels of the EWS/Fli1 oncofusion, suggesting that the drug could be uncoupling EWS/Fli1 from its oncogenic program. All Ewing Sarcoma cell lines examined also manifest increased DNA damage upon JIB-04 treatment. Together, the findings suggest that JIB-04 acts via multiple mechanisms to compromise Ewing Sarcoma cell growth and viability.

AB - Ewing Sarcoma is an aggressive malignant neoplasm affecting children and young adults. Ewing Sarcoma is driven by transcription factor fusion oncoproteins, most commonly EWS/Fli1. While some patients can be cured with high-dose, multiagent, chemotherapy, those that cannot currently have few options. Targeting of the driver oncofusion remains a logical therapeutic approach, but has proven difficult. Recent work has pointed to epigenetic mechanisms as key players, and potential new therapeutic targets, in Ewing Sarcoma. In this study we examined the activity of the pan-JHDM pharmacologic inhibitor JIB-04 in this disease. We show that JIB-04 potently inhibits the growth and viability of Ewing Sarcoma cells, and also impairs tumor xenograft growth. Effects on histone methylation at growth-inhibitory doses vary among cell lines, with most cell lines exhibiting increased total H3K27me3 levels, and some increased H3K4me3 and H3K9me3. JIB-04 treatment widely alters expression of oncogenic and tumor suppressive pathways, including downregulation of known oncogenic members of the Homeobox B and D clusters. JIB-04 also disrupts the EWS/Fli1 expression signature, including downregulation of pro-proliferative pathways normally under positive oncofusion control. Interestingly, these changes are accompanied by increased levels of the EWS/Fli1 oncofusion, suggesting that the drug could be uncoupling EWS/Fli1 from its oncogenic program. All Ewing Sarcoma cell lines examined also manifest increased DNA damage upon JIB-04 treatment. Together, the findings suggest that JIB-04 acts via multiple mechanisms to compromise Ewing Sarcoma cell growth and viability.

KW - Demethylase

KW - Epigenetics

KW - Ewing Sarcoma

KW - Inhibitor

KW - Jumonji

UR - http://www.scopus.com/inward/record.url?scp=85052938098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052938098&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26011

DO - 10.18632/oncotarget.26011

M3 - Article

AN - SCOPUS:85052938098

VL - 9

SP - 33110

EP - 33123

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 69

ER -